Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Oak Tree who wrote (3018)	3/3/2001 11:49:50 PM
From: Jibacoa	Respond to of 52153

.NOVT closed above the Feb.,Jan.,Dec. & Nov. Hs, If it can close above the Oct. H at 44 1/2 it could go to try for the Jun.,Jul.& Aug Hs at the 60-61 level, although under the present market conditions that possibility seems unlikely<g> Yesterday's volume of 534,100 was above the recent 10 days average (241,000) and the 3 months average (300,000). The intra-day H of 39 1/2 was at 1.48PM and the largest one minute volume was 41,900 at 1.57PM, which was mainly on upticks from 37 7/8 to 38 1/8. The institutions, that hold 118% of the float, reportedly have been buying lately, although the insiders have been selling: biz.yahoo.com The short position is about 7.8% of the float and 3xthe average daily volume.There are only 16.1 million shares out. They reportedly have $3.56 cash/share and lost $2.12 in the last year. I am aware that the stent use has markedly increased in the past 2 years since I have been retired and is now being used in multivessel lesions which previously were only candidates for ACBGs as PTCA was not considered an option. In Jan. BC/BS assessment of Betha-Cath found evidence that brachytherapy was an effective treatment of in-stent restenosis. Concerning the results that are due of the non-stent trial, how does brachytherapy compares on a cost basis with stents ? If you are looking for a pullback, depending on Monday's market conditions, the most-likely support levels are 34 1/2 (the level of the intermediate short term average) and the 33 7/8 to 34 area (the level of several Feb.'s intra-day Hs.) NOVT gave a buy signal on the 60 min.chart yesterday at 11.30AM at 34 1/16 and it is on a near term uptrend (withe the 3 short term averages on the right sequence). This near term uptrend should be maintained unless it drops below the 33 1/4 support level. RAGL Bernard

To: Oak Tree who wrote (3018)	3/4/2001 12:44:05 AM
From: Jibacoa	Respond to of 52153

Regarding NOVT, just a short note to clarify some points of my previous posting. (Don't want to make it too long to avoid any admonishment from Peter) You can see that when the price went through the 34 resistance, the momentum accelerated although the short term average had been above the longer average since Feb.26 when just below the 32 level it crossed over. siliconinvestor.com On the weekly chart you can see how the uptrend last year was maintained from Jan. until mid-September. Although the price had been lower before, the short term average had remained above the longer one until the 49 level. siliconinvestor.com I use 3 averages in my charts and they also give me some extra details that I find useful. Bernard

To: Oak Tree who wrote (3018)	3/15/2001 4:26:11 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

Will drug eluting stents cause an early demise of the recently approved beta & gamma radiation therapies ? Jeffery Popma,M.D, from Brigham and Women's Hosp. and Patrick W.Serruys M.D. from Erasmus Univ. in Rotterdam have been reporting good results with the drug-eluting stents (like Quanam's QuaDS) Since they don't require any special technique or equipment, they feel that the new stents will gradually displace the use of brachytherapy. In the mean time NOVT stock has to deal with the nearest resistance in the 35 area before it could try for the double top at the 39 1/2 level. siliconinvestor.com Bernard